Tomography News and Research

RSS

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.

10 Jun 2014

REM sleep disorder: A sign of impending neurodegenerative disease

How many millions of people suffer from sleep disturbance? One sleep disorder in particular, called REM behavior disorder, could be a sign of impending neurodegenerative disease, including Parkinson's and dementia, say scientists presenting their research at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Children who undergo complex imaging tests may have increased risk of cancer

Children with heart disease are exposed to low levels of radiation during X-rays, which do not significantly raise their lifetime cancer risk.

10 Jun 2014

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells-specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

10 Jun 2014

Dopamine transporter availability predicts ICDs

Reduced striatal dopamine transporter availability is already present in patients with Parkinson’s disease who go on to develop impulse control disorders, a study shows.

5 Jun 2014

Gamma and neutron imaging safe and effective in simulations

Gamma and neutron imaging offer possible improvements over existing techniques such as X-ray or CT, but their safety is not yet fully understood.

5 Jun 2014

Congress supports full Medicare coverage of lung cancer screening for seniors

A large number of United States Senators and Representatives are taking the lead to support full Medicare coverage of low-dose computed tomography (LDCT) screening for seniors at high risk for lung cancer.

5 Jun 2014

Endocrine Society publishes Clinical Practice Guideline for treatment of rare adrenal tumors

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of two types of rare adrenal tumors - pheochromocytomas and paragangliomas - that can raise the risk of cardiovascular disease and even death if left untreated.

4 Jun 2014

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.

2 Jun 2014

GE Healthcare to supply technetium-99m generators following FDA approval

Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for the production of sodium pertechnetate; technetium (Tc99m) injection to its radiopharmacies in the US.

31 May 2014

Chest CT helps identify individuals at risk for future heart attacks

Incidental chest computed tomography (CT) findings can help identify individuals at risk for future heart attacks and other cardiovascular events, according to a new study published online in the journal Radiology.

27 May 2014

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial.

23 May 2014

New "18F radiotracers" to detect and track certain diseases in patients

Radioactivity is usually associated with nuclear fallout or comic-book spider bites, but in very small amounts it can be a useful tool for diagnosing diseases.

22 May 2014

Bendamustine modestly efficacious but well tolerated in SCLC

Patients with relapsed or treatment-resistant small-cell lung cancer can achieve modest survival benefits with few side effects when treated with bendamustine, report US researchers.

21 May 2014

New optical approach to brain scanning for patients with electronic implants

Scientists have advanced a brain-scanning technology that tracks what the brain is doing by shining dozens of tiny LED lights on the head. This new generation of neuroimaging compares favorably to other approaches but avoids the radiation exposure and bulky magnets the others require, according to new research at Washington University School of Medicine in St. Louis.

20 May 2014

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

Presynaptic dopaminergic lesion predicts drug-induced dyskinesia

Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson’s disease will later develop levodopa-induced dyskinesia.

19 May 2014

Scan may rule out Parkinson’s disease

Patients with clinical symptoms of early Parkinson’s disease but no evidence of dopaminergic deficit on brain imaging are unlikely to have the condition, say the PRECEPT Study investigators.

19 May 2014

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014